Why the study?
Balancing the risk of perioperative bleeding against the risk of life-threatening thrombotic events from stopping antithrombotic therapy in ambulatory eye surgery requires clear management evidence.
Does perioperative antithrombotic management affect bleeding and thromboembolic events in patients undergoing ambulatory eye surgery?
Does perioperative antithrombotic management affect bleeding and thromboembolic events in patients undergoing ambulatory eye surgery?
For most ambulatory eye surgeries, continuing antithrombotic therapy carries a lower risk than stopping it, highlighting the need for individualized perioperative management.
Supports continuing antithrombotics in most ambulatory eye procedures; reinforces consensus favoring thrombotic risk minimization.
One of the most common surgeries in elderly patients is eye surgery. An increasing number of patients undergoing ambulatory eye surgery are on antithrombotic therapy. These drugs may increase the risk of perioperative bleeding associated with ophthalmic needle blocks and/or eye surgery. Intraoperative bleeding and postoperative hemorrhagic complications may lead to the loss of vision or even eyes. On the other hand, stopping anticoagulants and antiplatelets before the surgery may increase the risk of thrombotic events with potentially life-threatening complications. The aim of this narrative review is to provide a systematic review of the published evidence for the perioperative antithrombotic management of patients undergoing different types of eye surgery in ambulatory settings. A comprehensive review of the English-language medical literature search utilizing PubMed, Ovid Medline® and Google Scholar from January 2015 to December 2018 was performed. The database searches included studies providing evidence relevant to ambulatory eye surgery and perioperative antiplatelet medications and anticoagulants. Updated recommendations will be given for continuation, discontinuation, and modification of antithrombotic agents in order to optimize the management of antithrombotic therapies in outpatients scheduled for eye surgery.
No takes yet. Share an insight, caveat, or question.
Tatjana Śimurina (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: